Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
AFFiRiS AG
ChemoCentryx Inc
Dompe Farmaceutici SpA
Inte Pharma SA
Integral Molecular Inc
MorphoSys AG
Prommune Inc
Teva Pharmaceutical Industries Ltd
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Antagonize C5AR1 for Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestil, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target C5a for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News & Press Releases
Jan 24, 2019: ChemoCentryx announces withdrawal of phase II-based conditiol marketing authorisation (CMA) application for ANCA-associated vasculitis in Europe, phase III advocate trial data release planned for Q4 2019
Oct 25, 2018: ChemoCentryx announces presentation of data on Avacopan, a complement 5a receptor inhibitor, at ASN Kidney Week 2018
Sep 12, 2018: Inte pharma announces enrollment of first patient in the Phase I study of IPH5401 in combition with durvalumab (Imfinzi) in solid tumors
May 23, 2018: ChemoCentryx Announces Presentation On Avacopan at the 55th ERA-EDTA Congress
Apr 11, 2018: ChemoCentryx Announces Presentation During tiol Kidney Foundation 2018 Spring Clinical Meeting
Jan 04, 2018: Avacopan Conditiol Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Nov 03, 2017: ChemoCentryx Presents Data On Avacopan at ASN Kidney Week 2017
Sep 11, 2017: Inte Pharma Presents New Preclinical Data For IPH5401 at 3rd CRI-CIMT-EATI-AACR Intertiol Cancer Immunotherapy conference
Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan
May 23, 2017: ChemoCentryx Granted EU Orphan Drug Desigtion for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Desigtion for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan
Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (?CLEAR’ and ?CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (?Avacopan’)
Oct 27, 2016: ChemoCentryx Reports Improvement in Rel Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy
Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AFFiRiS AG, H1 2019
Pipeline by ChemoCentryx Inc, H1 2019
Pipeline by Dompe Farmaceutici SpA, H1 2019
Pipeline by Innate Pharma SA, H1 2019
Pipeline by Integral Molecular Inc, H1 2019
Pipeline by MorphoSys AG, H1 2019
Pipeline by Prommune Inc, H1 2019
Pipeline by Teva Pharmaceutical Industries Ltd, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Discontinued Products, H1 2019